 WATERTOWN, Mass., June 16, 2021 GLOBE NEWSWIRE -- C4 Therapeutics, Inc. C4T Nasdaq: CCC, a clinical-stage biopharmaceutical company pioneering a new class of small-molecule medicines that selectively destroy disease-causing proteins through degradation, today announced the pricing of an underwritten public offering of 4,250,000 shares of its common stock at a public offering price of 37.00 per share. 